Peptide-receptor radionuclide therapy for endocrine tumors
- 2 June 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Endocrinology
- Vol. 5 (7), 382-393
- https://doi.org/10.1038/nrendo.2009.105
Abstract
Peptide-receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is a promising option for the treatment of somatostatin-receptor-positive endocrine tumors. Treatment with somatostatin analogs labeled with (111)In, (90)Y or (177)Lu can result in symptomatic improvement, although tumor remission is seldom achieved with (111)In-labeled analogs. In this Review, the findings of several studies on the use of PRRT for endocrine tumors are evaluated. Large variation in the antitumor effects of (90)Y-octreotide was reported between studies: an objective response (> or =50% tumor regression) was achieved in 9-33% of patients. After treatment with (177)Lu-octreotate, an objective response was achieved in 29% of patients and a minor response (25-50% tumor regression) was achieved in 16% of patients; stable disease was present in 35% of patients. Treatment with (177)Lu-octreotate resulted in a survival benefit of several years and markedly improved quality of life. Serious, delayed adverse effects were rare after PRRT. Although randomized, clinical trials have not yet been performed, data on the use of PRRT compare favorably with those from other treatment approaches, such as chemotherapy. If these results can be replicated in large, controlled trials, PRRT might become the preferred option in patients with metastatic or inoperable gastroenteropancreatic neuroendocrine tumors.Keywords
This publication has 61 references indexed in Scilit:
- Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitroNuclear Medicine and Biology, 2006
- Radiolabeled somatostatin receptor antagonists are preferable to agonists forin vivopeptide receptor targeting of tumorsProceedings of the National Academy of Sciences, 2006
- Alkaline Phosphatase Predicts Survival in Patients with Metastatic Neuroendocrine TumorsDigestive Diseases and Sciences, 2006
- Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic)Neuroendocrinology, 2006
- Chemotherapy for Gastro-Enteropancreatic Endocrine TumoursNeuroendocrinology, 2004
- Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner TumorenDer Onkologe, 2004
- Quality of Life in Patients With Gastroenteropancreatic Tumors Treated With [177Lu-DOTA0,Tyr3]octreotateJournal of Clinical Oncology, 2004
- Long-Term Management of the Carcinoid Syndrome Treatment with octreotide alone and in combination with alpha-interferonActa Oncologica, 1993